Skip to main content

Table 4 Model specifications and reported statistics by study endpoint

From: Indirect comparison of intravenous vs. subcutaneous C1-inhibitor placebo-controlled trials for routine prevention of hereditary angioedema attacks

Endpoint Model Reported statistics
Mean difference in monthly attacks SAS PROC MIXED: fixed effects: treatment, period, sequence, random effect: subject within treatment Point estimates for treatment effect over placebo and 95% CI; difference of treatment effects between C1-INH(SC) and C1-INH(IV), 95% CI and P-value
Median difference in monthly attacks SAS PROC QUANTREG: fixed effects: treatment, sequence within treatment
% reduction in monthly attacks SAS PROC MIXED: fixed effects: treatment, period, sequence within treatment
Median % reduction in monthly attacks SAS PROC QUANTREG: fixed effects: treatment, sequence within treatment
Number of patients with ≥ × % reduction SAS PROC GLIMMIX: fixed effects: treatment, sequence within treatment Percentage of patients; odds ratio C1-INH(SC) over C1-INH(IV) and P-value
  1. CI confidence interval